The 5th Innate Killer Summit is the leading industry meeting providing a platform for leaders in the NK, gdT and NKT fields to network, interact and learn. This 3-day meeting is the only end-to-end platform that fosters the transformation of leading science to life-changing commercial therapies.
As the understanding of innate cells improves year on year, the challenges of producing effective cell therapies are top priorities to overcome. Manufacturing processes need to be streamlined and regulatory landscapes better understood. It is imperative that we come together as a community to exchange ideas and overcome the hurdles of getting the best immunotherapies to patients in need.
In addition to accessing cutting-edge novel innovations and the latest clinical data, leave the Innate Killer Summit fully equipped to progress your cell therapy pipeline with actionable insights and a forward-looking plan for global manufacturing.
Join world renowned academics and industry experts from all the key stakeholders to identify future approaches and deliver commercially viable off-the-shelf therapies.
Conference + Bootcamp (Drug Developer Rate): USD 3798.0,
Conference Only (Drug Developer Rate): USD 2899.0,
Bootcamp Only (Drug Developer Rate): USD 999.0,
Conference + Bootcamp (Solution Provider Rate): USD 4498.0,
Conference Only (Solution Provider Rate): USD 3499.0,
Bootcamp Only (Solution Provider Rate): USD 1199.0
Speakers: Sonny Hsiao, CEO, Acepodia, Stewart Abbot, CSO, Adicet Bio, Joachim Koch, Head Translational Reseach and Innovaiton, Affimed GmbH, Peter Flynn, CTO Artiva, Biotherapeutics Inc., Robin Parihar, Assistant Proffesor, Baylor College of Medicine, Noah Merin, Professor, Cedars-Sinai Medical Centre, Nassir Habboubi, CMO, Celularity, Emily Mace, Assistant Proffesor, Columbia University in the City of New York, Michael Koslowski, CMO, GammaDelta Therapeutics, Rizwan Romee, Director - Haploidentical Donor Transplantation Program, Dana-Farber Cancer Institute, Bob Valamehr, CDO, Fate Therapeutics, Amy Sharma, Scientist and Toxicologist, Safety Assessment, Early Development, Genetech, Yu-Kyeong Hwang, SVP and Head of Research and Development, Greencross, Amir Horowitz, Professor, Icahn School of Medicine at Mount Sinai, Larry Lamb, CSO, Incysus, Evren Alici, CEO, Vycellix, Jeffrey Miller, Professor, University of Minnesota, Elie Haddad, Professor of Paediatrics, University of Montreal, Dean Lee, Director, Cellular Therapy and Cancer Immunotherapy, Nationwide Children's Hospital, Michael O’Dwyer, Professor, NUI Galway, Nick Huntington, CSO, oNKo-Innate Pty Ltd, Karl-Johan Malmberg, Professor, Oslo University, Silke Paust, Associate Professor, Scripps Institute, Carsten Watzl, Professor, Technical University Dortmund, Donna Rill, CTO Triumvira, Immunologics Inc, Anahid Jewett, Professor, University of California Los Angeles, Dan Kaufman, Professor, University of California, Alicja Copik, Research Assistant Professor, University of Central Florida, Alan Epstein, Professor, University of Southern California Keck School of Medicine, Todd Fehniger, Associate Professor, Washington University School of Medicine in St Louis, James Trager, CSO, Nkarta Therapeutics, Cristina Argaiz Equizabal, Chief of Research Unit, Basque Center for Transfusion and Human Tissue
Time: 9:00 am to 5:00 pm